Midkine Protein Shows Potential to Inhibit Alzheimer's Amyloid Formation
Scientists have discovered that the protein midkine may inhibit the formation of amyloid beta plaques, offering new hope for Alzheimer's disease treatment strategies.
Recent research conducted by scientists at St. Jude Children's Research Hospital has uncovered a promising new role for the protein midkine in the fight against Alzheimer's disease. Published in Nature Structural & Molecular Biology on August 21, 2025, the study reveals that midkine can prevent the growth of amyloid beta assemblies, which are closely associated with the development of Alzheimer's. The team demonstrated that midkine interacts with amyloid beta proteins, inhibiting their ability to stick together and form the toxic plaques characteristic of the disease.
Midkine, a small growth factor abundantly present during embryonic development and involved in cell proliferation, has traditionally been studied in the context of cancer due to its overexpression in various tumors. Its connection to neurodegeneration was less understood until now. In the study, scientists utilized advanced techniques such as fluorescence assays, circular dichroism, electron microscopy, and nuclear magnetic resonance to explore the interaction between midkine and amyloid beta. The findings showed that midkine effectively hampers the elongation and secondary nucleation phases of amyloid beta assembly, thereby reducing the formation of harmful fibrils.
The researchers further confirmed the protective effect of midkine using Alzheimer’s disease mouse models. Mice lacking the midkine gene exhibited increased amyloid beta accumulation, highlighting the protein’s potential to naturally counteract plaque buildup. These insights open new avenues for drug development, aiming to mimic or enhance midkine's interaction with amyloid beta. Future strategies may involve designing small molecules that replicate midkine's activity to prevent or slow down Alzheimer’s pathology.
This groundbreaking discovery positions midkine as a promising biomolecular target for Alzheimer’s treatment, offering hope for interventions that could modify disease progression by controlling amyloid beta aggregation. Continued research aims to better understand the precise mechanism of midkine’s binding to amyloid beta and to develop therapeutic agents that harness this natural protective effect.
Source: https://medicalxpress.com/news/2025-08-midkine-protein-blocks-alzheimer-amyloid.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovation in Brain Imaging: Reversible Transparency Technique in Mice
Stanford researchers have pioneered a reversible, non-invasive technique to make mouse scalps transparent, enabling detailed studies of brain development and neural activity in vivo, opening new horizons in neuroscience research.
Innovative WiFi Technology Enables Heart Rate Monitoring Without Wearables
A new study from UC Santa Cruz introduces Pulse-Fi, a system that uses standard Wi-Fi signals and machine learning to monitor heart rate accurately without wearable devices, opening new possibilities for accessible health tracking.
Bystander T Cells Enhance the Effectiveness of Bispecific Antibody Therapy in Cancer Treatment
New research emphasizes the role of bystander T cells in enhancing the effectiveness of bispecific antibody therapy in lymphoma treatment, potentially improving patient outcomes through sequential CAR-T and BsAb approaches.
Study Finds Cannabinoid Products May Shorten Sleep Duration in Adults with Insomnia
A recent study reveals that a single dose of medicinal cannabis may decrease total sleep time and REM sleep in adults with insomnia, highlighting the need for further research into its effects on sleep health.